GLRA
AGIO icon

Gerald L. Ray & Associates’s Agios Pharmaceuticals AGIO Stock Holding History

Gerald L. Ray & Associates’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$1.97M Sell
29,465
-3,900
-12% -$234K 0.25% 96
2017
Q2 		$1.72M Sell
33,365
-1,350
-4% -$69K 0.22% 105
2017
Q1 		$2.03M Buy
34,715
+1,300
+4% +$62.3K 0.28% 84
2016
Q4 		$1.39M Sell
33,415
-1,900
-5% -$99.7K 0.2% 110
2016
Q3 		$1.86M Buy
35,315
+850
+2% +$37K 0.28% 88
2016
Q2 		$1.44M Buy
34,465
+14,390
+72% +$711K 0.23% 96
2016
Q1 		$815K Buy
20,075
+7,680
+62% +$328K 0.13% 134
2015
Q4 		$805K Buy
12,395
+730
+6% +$47.9K 0.13% 142
2015
Q3 		$823K Buy
11,665
+200
+2% +$19.5K 0.14% 134
2015
Q2 		$1.27M Buy
11,465
+3,245
+39% +$350K 0.19% 112
2015
Q1 		$775K Buy
8,220
+1,370
+20% +$154K 0.12% 162
2014
Q4 		$767K Buy
+6,850
New +$612K 0.12% 157

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Gerald L. Ray & Associates's AGIO Position: Q3 2017 in Review

Gerald L. Ray & Associates reduced its Agios Pharmaceuticals (AGIO) stake by 12% in Q3 2017, selling an estimated $234K and leaving 29,465 shares worth $1.97M. The position accounts for 0.25% of the portfolio, ranked #96.

Gerald L. Ray & Associates first reported a position in AGIO in Q4 2014 and has held it in 12 quarters since. The position peaked at $2.03M in Q1 2017. 171 funds tracked by Wall St. Rank hold AGIO as of Q3 2017.

  • Gerald L. Ray & Associates held 29,465 shares of Agios Pharmaceuticals worth $1.97M as of Q3 2017.
  • Gerald L. Ray & Associates sold 3,900 Agios Pharmaceuticals shares in Q3 2017, an estimated $234K.
  • Agios Pharmaceuticals made up 0.25% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #96 holding.
  • Gerald L. Ray & Associates first reported a position in Agios Pharmaceuticals in Q4 2014 and has held it in 12 quarters since.
  • Gerald L. Ray & Associates's Agios Pharmaceuticals position peaked at $2.03M in Q1 2017.
  • 171 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.